Sponsor pipeline

Acerta Pharma BV clinical trial pipeline

Get alerts when Acerta Pharma BV's trials change

15 active trials 0 recruiting 6 Phase 3 6 disease areas 1 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days

2026-08-26
minor
Completion pushed: 2025-09-30 → 2026-09-15
NCT02475681 Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL · Phase 3

Active trials by phase

Phase 1
3
Phase 1/2
3
Phase 2
3
Phase 3
6

Active trials

NCT IDTitleConditionStatusUpdated
Phase 3
NCT02477696 Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With… Chronic Lymphocytic Leukemia Active, Not Recruiting 2026-08-26
NCT02475681 Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL Chronic Lymphocytic Leukemia Active, Not Recruiting 2026-08-25
NCT02970318 A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or… Chronic Lymphocytic Leukemia Active, Not Recruiting 2026-07-24
NCT04529772 A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB… Diffuse Large B-Cell Lymphoma Active, Not Recruiting 2026-06-25
NCT02972840 A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously… Lymphoma, Mantle Cell Active, Not Recruiting 2026-06-01
NCT03836261 Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and… Chronic Lymphocytic Leukemia Active, Not Recruiting 2024-12-27
Phase 2
NCT02213926 An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell… Mantle Cell Lymphoma (MCL) Active, Not Recruiting 2026-08-04
NCT02180724 An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia Waldenström Macroglobulinemia (WM) Active, Not Recruiting 2026-06-16
NCT02717611 A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and… Chronic Lymphocytic Leukemia Active, Not Recruiting 2026-03-25
Phase 1/2
NCT02180711 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell… Non Hodgkin Lymphoma Active, Not Recruiting 2026-07-08
NCT02029443 ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of… Chronic Lymphocytic Leukemia Active, Not Recruiting 2026-05-05
NCT02586857 A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent… Glioblastoma Multiforme Active, Not Recruiting 2026-03-25
Phase 1
NCT02717624 A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in… Mantle Cell Lymphoma (MCL) Active, Not Recruiting 2026-07-14
NCT03328273 A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic… Chronic Lymphocytic Leukemia Active, Not Recruiting 2026-07-14
NCT02157324 Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia Active, Not Recruiting 2025-08-13

Disease areas by active trials

Get alerts when Acerta Pharma BV's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free